Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01453140 · ClinicalTrials.gov registry record · Phase 1
In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus
A Phase 1 study, sponsored by Hackensack Meridian Health.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01453140 is a Phase 1 study that was terminated before completion, run by Hackensack Meridian Health. The registered enrollment target is 3 participants.
The verdict
NCT01453140, a Phase 1 study, was terminated before completion, sponsored by Hackensack Meridian Health.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
In this study the investigators are proposing to treat patients with steroid-refractory Graft-versus-host Disease (GVHD) stabilization using IL-2 and azacitidine
Interventions
- DRUG Cyclophosphamide and Sirolimus
- DRUG Low dose IL-2 with Cytoxan + Sirolimus
- DRUG Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01453140
The ClinicalTrials.gov registry entry for NCT01453140 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide and Sirolimus is the first listed.
NCT01453140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01453140 about?
NCT01453140 is a clinical study titled "In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus". In this study the investigators are proposing to treat patients with steroid-refractory Graft-versus-host Disease (GVHD) stabilization using IL-2 and azacitidine
What is the current status of trial NCT01453140?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2011-08. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01453140?
The interventions under investigation include: Cyclophosphamide and Sirolimus (DRUG), Low dose IL-2 with Cytoxan + Sirolimus (DRUG), Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus (DRUG).
Who is sponsoring clinical trial NCT01453140?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.